Is Wall Street Bullish or Bearish on Hologic Stock?

Company Overview - Hologic, Inc. (HOLX) is a global medical technology company with a market cap of $16.7 billion, focused on improving women's health through early disease detection and treatment [1] - The company develops and supplies diagnostic assays, medical imaging systems, and surgical solutions across its Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments [1] Stock Performance - Over the past 52 weeks, HOLX shares have increased by 16.2%, outperforming the S&P 500 Index, which gained 15.6% [2] - Year-to-date, HOLX stock has risen marginally, lagging behind the S&P 500's 1.7% return [2] - HOLX shares have outpaced the State Street Health Care Select Sector SPDR ETF (XLV), which returned 6.8% over the same period [3] Recent Financial Results - Following Q1 2026 results released on January 29, shares of Hologic fell marginally; adjusted EPS was $1.04 and revenue totaled $1.05 billion, both below expectations [5] - The decline in investor sentiment was attributed to weakness in Diagnostics revenue, margin compression due to $15.3 million in tariff-related costs, and the lack of forward guidance due to a pending acquisition by Blackstone and TPG [5] Future Earnings Expectations - For the fiscal year ending in September 2026, analysts expect HOLX's adjusted EPS to grow by 4.9% year-over-year to $4.47 [6] - The company's earnings surprise history is mixed, having topped consensus estimates in three of the last four quarters while missing on one occasion [6] - Among the 18 analysts covering the stock, the consensus rating is a "Hold" [6] Price Target - The mean price target for HOLX is $75.58, representing a marginal premium to its current price [8] - The highest price target of $79 suggests a potential upside of 5.3% [8]